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Abstract
Background: Quantitative real-time PCR assays, which are more rapid and practical than pp65
antigenemia determination, are progressively becoming the preferred method for monitoring
Human Cytomegalovirus (HCMV) reactivation. However, the relationship between HCMV DNA
and antigenemia levels is still under investigation. The aim of this study was to analyse the
relationship between HCMV DNA and pp65 antigenemia levels in order to identify clinically useful
threshold values for the management of patients.
Methods: 475 consecutive samples from 156 immunosuppressed patients were tested for HCMV
by pp65 antigenemia and Real-time PCR assay.
Results : 136 out of 475 consecutive samples derived from 48 patients showed evidence of HCMV
infection. HCMV DNA was detected in 106 samples, pp65 antigen in 3, and both markers in 27.
pp65 antigen detection was associated with higher HCMV DNA levels. The cut-off HCMV DNA
level that best predicted pp65 antigenemia in this series of samples was 11,500 copies/ml, but
different threshold levels could be observed for specific groups of patients. HCMV disease was
observed in 5 out of 48 patients with active HCMV infection. The presence of clinical symptoms
was associated with positive pp65 and with higher antigenemia levels. Higher HCMV DNA load at
the onset of viral replication was correlated to the development of clinical symptoms.
Conclusion: Both pp65 antigenemia and HCMV DNA load can be useful for the prospective
monitoring of immunocompromised subjects. Specific cut-off levels capable of triggering
preemptive antiviral treatment should be determined in accordance to the type of test used and
the characteristics of patients and prospectively validated.
Background
Human Cytomegalovirus (HCMV) is the cause of lifelong
latent infection in immune competent host. HCMV reac-
tivation is a frequent event and represents a significant
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cause of morbidity and mortality in immunocompro-
mised patients. The availability of diagnostic assays for
the early identification of reactivated HCMV replication
has considerably improved the clinical management of
immunocompromised patients, thus reducing the risk of
HCMV disease and allowing pre-emptive treatment as an
alternative to universal prophylaxis. The determination of
pp65 antigenemia has long been the reference test for
monitoring HCMV reactivation [1-4], but it requires
highly skilled interpretation and processing of fresh sam-
ples [5,6]. Furthermore, the evaluation of its results may
be particularly difficult in leukopenic patients [7]. More
recently, the quantitation of HCMV DNA by real-time
PCR methods has been proposed as a convenient alterna-
tive approach, in order to overcome the drawbacks of anti-
genemia assays [7-17]. The exact relationship between
HCMV DNA and antigenemia levels, however, is still
under investigation. Studies addressing this issue would
be instrumental in finding suitable threshold levels for the
clinical interpretation of HCMV DNA results.
Methods
Patients
From June 2004 to March 2005, a total of 475 consecutive
blood samples were received by our Laboratory for the
simultaneous determination of pp65 antigenemia and
quantitative HCMV DNA in plasma. The samples came
from 156 patients (56 females, 100 males, mean age 44.4
± 18.4 years). The median number of samples per patient
was 8 (range: 6–28).
Patients included 75 (48%) kidney transplant (KT) recip-
ients, 18 (11.5%) bone marrow/stem cell transplant
(BMT/HSCT) recipients (including 16 pediatric and 2
adult patients), 34 (21.8%) patients with advanced
human immunodeficiency virus (HIV) infection and 29
(18.5%) patients with haematological malignancies.
Active HCMV infection was defined as the detection of
HCMV antigenemia and/or DNAemia. HCMV disease was
defined as the association of active infection with clinical
symptoms such as: unexplained fever (> 38°C), leukope-
nia (white blood cells < 3.5 × 109 /l) and/or thrombocyto-
penia (platelet count < 100 × 109/l), gastrointestinal
symptoms, artrhalgia, myalgia in KT recipients; fever, leu-
kopenia, hepatitis, enteritis, retinitis or pneumonitis in
BMT/HSCT recipients; colitis, oesophagitis, hepatitis,
encephalitis or retinitis in patients with advanced HIV
infection; fever and neutropenia (< 500 neutrophilis/ul)
in haematological patients.
No antiviral prophylaxis was given to KT recipients, that
received steroids (methylprednisolone 500 mg IV) before
transplantation. In addition the patients received either
an anticalcineurin agent or sirolimus. Intravenous ganci-
clovir or valganciclovir was administered when 50 or
more pp65-antigen positive cells were detected. BMT/
HSCT recipients underwent standard prophylaxis for bac-
terial and fungal infections, and received acyclovir 5 mg/
kg body weight. Prophylaxis for HCMV infection was not
administered. Intravenous ganciclovir (5 mg/kg of body
weight every 12 h for 14 days, adjusted to renal function)
was started when > 1 pp65-positive cells/200,000 PMNL
were detected, or after two consecutive HCMV DNA-posi-
tive samples. The same criteria were used for pre-emptive
treatment of haematological patients. Patients with
advanced HIV infection had CD4 cell count < 100 × 106/l
and positive HCMV serology. They received antiretroviral
therapy but no HCMV prophylaxis. Antiviral therapy was
started when > 100 pp65 -antigen positive cells/200,000
PMNL and/or HCMV DNA load > 100,000 copies/ml was
detected.
The donor/recipient serological status was determined
before transplantation by a commercially available
enzyme-linked immunosorbent assay (BEIA CMV IgG
Quant, Bouty, Italy) according to the manufacturer's
instructions.
All transplanted patients were monitored for the presence
of active HCMV replication for 6 months after transplan-
tation. Determination of HCMV DNA load and of pp65
antigenemia was carried out once (in the absence of
HCMV reactivation) or twice a week (during HCMV active
replication) until disappearance of antigenemia and/or
DNAemia; subsequently, HCMV replication was moni-
tored monthly. HIV-infected and haematological patients
were monitored monthly during routine clinical controls.
In the presence of clinical signs or symptoms suggestive of
HCMV disease monitoring was carried out once a week.
HCMV pp65 antigenemia assay
Twin blood samples were collected in citrate-anticoagu-
lated tubes for pp65 antigenemia and quantitative real-
time PCR. One sample was processed for antigenemia
within 4 hours, and the other was stored for quantitative
plasma DNA determination. The determination of HCMV
antigenemia was carried out using a HCMV BriteTurbo kit
(Lagitre U.S.A.) according to the manufacturer's instruc-
tions. The number of pp65-positive polymorphonuclear
leukocytes (PMNL) was determined after staining with
specific fluorescein isothiocyanate-labelled monoclonal
antibodies, with results expressed as the number of posi-
tive cells per 200,000 PMNL.
HCMV DNA quantitation
DNA extraction from plasma (200 µl) was performed
using a QiaAmp DNA Mini Kit (Qiagen, Germany)
according to the manufacturer's instructions. HCMV DNA
quantitation was carried out by a commercially availableBMC Infectious Diseases 2007, 7:138 http://www.biomedcentral.com/1471-2334/7/138
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real-time PCR test: TaqMan Q-CMV Real Time System
(Cepheid, Nanogen Advanced Diagnostic, USA). This test
is based on the simultaneous amplification of the HCMV
MIEA (Major Immediate Early Antigen) gene (HCMV
UL123-exon 4) and of internal control human beta globin
gene DNA, that was added to each sample at a known con-
centration during specimen processing to monitor DNA
extraction and recovery, amplification and detection. Spe-
cific TaqMan probes labelled with different reporter mol-
ecules (FAM/MGB-NFQ and VIC/MGB-NFQ) were used
for target quantitation by interpolation of fluorescent sig-
nal intensity with a standard curve derived from the
amplification of serially diluted HCMV DNA standards.
The assay was performed according to the manufacturer's
recommendations. Briefly, DNA (5 µl) was added to the
PCR mixture containing 5 mM MgCl2, 0.5 µM of each
primer and probe and 0.025 U of uracyl-N-glycosylase
(UNG). The PCR conditions were: decontamination at
50°C for 2 minutes, initial denaturation at 95°C for 10
minutes followed by 45 cycles of 15 sec at 95°C and 1
minute at 65°C. A plasmid containing UL123 gene
diluted to give a standard curve of 2 log10 to 5 log 10 cop-
ies per reaction was used as a standard for quantification.
PCR reactions were performed using an ABI Prism 7300
Sequence Detection System (PE Applied Biosystems). The
linear interval of the assay's analytical sensitivity as
assessed by the manufacturer was between 316 and 12.5 ×
106 HCMV DNA copies/ml of plasma.
Cost analysis
The costs of the assays were measured in terms of require-
ments for time, reagents or kits, and labour.
Statistical analysis
HCMV DNA levels were compared by Mann-Whitney U
test. The correlation between HCMV DNA and pp65 anti-
genemia was analysed using the Spearman correlation
coefficient.
The differences between groups were analysed using the
Chi-square test or the Fisher's exact test, as appropriate. A
P value of < 0.05 was considered as statistically significant.
Receiver-operating characteristic (ROC) curve analysis
was carried out on the MedCalc statistical software, ver-
sion 7.5.00.
Results
Analytical performance of the real-time PCR assay
To analyse the precision of the real-time PCR assay, inter-
and intra-assay variations were calculated by testing three
plasma pools containing samples with low (500–5,000
HCMV DNA copies/ml), intermediate (10,000–70,000
HCMV DNA copies/ml) and high (70,000–120,000
HCMV DNA copies/ml) viral load value. Intra- assay vari-
ation was evaluated by quantifying HCMV DNA load in
triplicate for each plasma pool while inter-assay variation
was calculated by analysing each plasma pool in four dif-
ferent assays.
The mean DNA loads (copies/ml) detected in the low,
intermediate and high titre plasma pools, and intra-/inter-
assay percent coefficients of variation (CV%) are shown in
Table 1.
Correlation between pp65 and HCMV DNA load
Of the 475 samples analysed, 339 (71.3%) were negative
for both HCMV DNA and pp65 antigenemia. The remain-
ing 136 samples, taken from 48 patients (20 females, 28
males, mean age 42.3 ± 17.8 years), were positive for
HCMV DNA (106 samples, 78.7%), pp65 antigenemia (3
samples, 2.2%), or both (27 samples, 19.1%). HCMV
assay results were discordant for 109 out of 475 samples
(22.95%). Altogether, 51 episodes of active HCMV repli-
cation (defined by positive results of HCMV DNA and/or
pp65 in at least two consecutive samples) were detected.
The overall pp65 antigenemia values were statistically cor-
related to HCMV DNA levels (p < 0.0001). All samples
containing detectable pp65 antigen had significantly
higher HCMV DNA levels (median: 59,230 copies/ml;
range: 0–1.47 × 106) compared to pp65-negative samples
(median: 2,830 copies/ml; range: 0–1.58 × 106) (p <
0.0001) (Figure 1).
Table 1: Reproducibility of real-time PCR with low-, intermediate-, and high-titre plasma pools.
PLASMA POOLS
PRECISION Low-titre Intermediate-titre High-titre
Mean value (copies/ml) CV% Mean value (copies/ml) CV% Mean value (copies/ml) CV%
Intra-assay 3,162 27.8 50,119 23.5 100,000 21.2
Inter-assay 3,981 28.8 63,096 23.3 107,000 26.7BMC Infectious Diseases 2007, 7:138 http://www.biomedcentral.com/1471-2334/7/138
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Significant differences were observed among median
HCMV DNA levels in the different risk groups (Table 2).
Samples from KT recipients contained significantly higher
HCMV DNA levels compared to those derived from BMT/
HSCT recipients (p < 0.0001), HIV-infected (p = 0.0056),
and haematological patients (p = 0.0001).
The cut-off HCMV DNA level that best predicted positive
pp65 antigenemia in the entire study population was
identified by ROC curve analysis as 11,500 copies/ml
(area under curve: 0.867; sensitivity: 88.9%; specificity:
79.2%). When the analysis was focused on single groups
of patients, different threshold values between pp65-pos-
itive and -negative samples were found in KT recipients
(cut-off: 24,000 copies/ml; area under curve: 0..888; sen-
sitivity: 100%; specificity: 78%) compared to BM/HSCT
recipients (cut-off: 9,960 copies/ml; area under curve:
0.605, sensitivity: 58.3%; specificity: 94.3%). The low
number of pp65-positive samples in the remaining
groups of patients (Table 2) did not allow for statistical
analysis. To better define the cost-effectiveness of pp65
and of HCMV DNA in predicting HCMV reactivation and
disease, we considered the cost and technical required
time of each determination. The real-time PCR assay for
HCMV DNA quantitation takes 180 minutes (DNA extrac-
tion included) with a total time for the production a
results of five hours, whereas the pp65 antigenemia pro-
cedure requires 300 minutes for single test and a time for
results of ten hours. The cost per sample with antigenemia
and real-time PCR tests are Euro 10.31 and Euro 35.09,
respectively.
Clinical utility of pp65 and HCMV DNA load
HCMV disease occurred rarely as symptomatic infection
was observed in 5 of 48 patients with active HCMV repli-
cation (10.4%). HCMV DNA was detected in all 48
patients whereas pp65 was detected in 11, including 5
with symptomatic infection (p < 0.001).
Among KT recipients (24 patients, 22 of which donor [D]
positive [+]/recipient [R] +, 1 D+/R negative [-], 1 D-/R-)
only one patient (D+/R-; 4.17%) developed symptomatic
infection (fever and leukopenia) 44 days after transplan-
tation. In this patient the diagnosis of HCMV infection
was based on the simultaneous detection of pp65 and
HCMV DNA. In the remaining 23 asymptomatic KT recip-
ients, diagnosis of HCMV reactivation was made due to
the detection of HCMV DNA with (4 cases) or without (20
cases) pp65.
HCMV disease symptoms, including fever, leukopenia,
increased aminotransferase levels, gastritis and pneumo-
nitis, were observed in 4 (66.6%) out of 8 BMT/HSCT D+/
R+ recipients during the first two months [range : 20–59
days] after transplantation. HCMV DNA preceded the
onset of symptoms and pp65 detection in 3 of 4 cases,
whereas pp65 and HCMV DNA appeared simultaneously
in the last patient. The remaining 4 asymptomatic BMT/
HSCT recipients only showed low-level HCMV DNA in
the absence of pp65. In the remaining patients asympto-
HCMV DNA levels in pp65-positive and -negative samples Figure 1
HCMV DNA levels in pp65-positive and -negative samples. 
The horizontal lines represent median HCMV DNA values in 
the two groups of samples.
Table 2: Detection of HCMV DNA and pp65 in different groups of patients
Groups n. positive patients (samples) Median HCMV DNA copies/ml (range)
HCMV DNA pp65
KT recipients 24 (66) 5 (16) 17,020 (438-1.58 × 106)
BMT/HSCT recipients 8 (44) 4 (12) 2,480 (316-3.1 × 105)
HIV 10 (14) 2 (2) 2,615 (240-2 × 105)
HM 6 (9) 0 1,100 (316-2,7 × 103)
Total 48 (133) 11 (30) 5,841 (240-1.58 × 106)
KT: kidney transplant; BMT/HSCT: bone marrow/stem cell transplant; HIV: patients with advanced human immunodeficiency virus infection; HM: 
patients with haematological malignancies.BMC Infectious Diseases 2007, 7:138 http://www.biomedcentral.com/1471-2334/7/138
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matic HCMV reactivation was diagnosed by the detection
of HCMV DNA alone (15 cases) or simultaneously with
pp65 (1 case). Altogether, HCMV DNA appeared before
antigenemia in 3 out of 5 patients developing symptoms
and in none of 6 pp65-positive patients without symp-
toms of HCMV disease.
In symptomatic patients 29.1% of samples were positive
for pp65 compared to 11.8% in asymptomatic patients (p
< 0.001) (Table 3). Moreover, symptomatic infection was
accompanied by higher pp65 levels (median: 30 cells/
200,000 PMNL, range 3–100, vs median: 11.5 cells/
200,000 PMNL, range 1–85, in asymptomatic patients; p
= 0.029). ROC curve analysis showed that the best cut-off
pp65 value predictive of symptomatic infection was 13
cells/200,000 PMNL (area under curve: 0.734; sensitivity:
81.2%, specificity: 57.1%). By contrast, median HCMV
DNA levels did not differ significantly between sympto-
matic (7,500 copies/ml) and asymptomatic patients
(4,580 copies/ml).
Median HCMV DNA level in the first positive sample was
22,400 copies/ml (range: 1830–520,000) in the 5 symp-
tomatic patients, and 2677 copies/ml (range: 280–
413,820) in the 43 asymptomatic patients (p = 0.029). By
contrast, the number of pp65 positive cells in the first pos-
itive sample did not differ significantly between sympto-
matic and asymptomatic patients (30 cells/200,000
PMNL, range 3–80, vs. 11 cells/200,000 PMNL, range 3–
85; p = 0.17). A HCMV DNA load > 7880 copies/ml at first
detection could predict the onset of symptoms with 80%
sensitivity and 79.1% specificity (area under curve:
0.800).
HCMV infection responded to ganciclovir in all patients.
The clinical monitoring of symptomatic patients during
treatment revealed that pp65 became undetectable after
8–17 days (median: 12.5 days), whereas HCMV DNA
decreased more slowly disappearing 7–105 days (median:
41 days) after the beginning of treatment. Similar results
were observed among patients without clinical symp-
toms: pp65 (detected in 6) disappeared after 7–20 days
(median: 14 days), whereas HCMV DNA persisted for 3 –
51 days (median: 33 days).
Discussion
HCMV pp65 antigenemia is known to be clinically useful
for the management of HCMV reactivation in immuno-
compromised patients [1-4]. Cut-off antigenemia levels
have been proposed as an option to trigger treatment in
different patient populations [18-20], which would
reduce the incidence of HCMV-related disease.
Real-time PCR methods for HCMV DNA quantitation
could offer a convenient alternative for monitoring
HCMV replication which is less influenced by the quality
of sample and more suited to standardization and auto-
mation, compared to antigen detection tests. In addition,
real-time PCR requires a small volume of plasma (200 µl)
compared to 3–5 ml of whole blood required for antigen-
emia, and can be done on neutropenic patients. Finally,
despite being considerably cheaper, pp65 requires longer
technical labour and longer time for the production of a
result and the processing of fresh samples.
Although several studies have already addressed this issue
[9,13,14,16,19-23], the correlation between antigenemia
results and real-time PCR, as well as the clinical signifi-
cance of both assays, requires further evaluation. When
we analysed a series of consecutive samples referred to our
laboratory, the sensitivity of the real-time PCR- based test
in detecting HCMV infection was considerably higher
than that of pp65 determination, although pp65 was
detected in 3 samples with no evidence of HCMV DNA.
These samples were consecutively derived from a single
HSCT recipient after a symptomatic episode of HCMV
reactivation with simultaneous detection of pp65 and
DNA (data not shown).
Discrepancies between the two HCMV markers may be
linked to the distinct viral components analysed here
(protein vs. genome), the different districts considered
(PMNL vs. plasma), the sensitivity threshold of the tests.
The observation of pp65-positive, HCMV DNA-negative
samples could be due to pp65 transfer from endothelial
cells to adhering PMNL, in the absence of viral replication
[13,24]. A significant correlation between pp65 antigene-
mia and HCMV DNA levels was demonstrated using a
non-parametric test, despite the wide dispersion of HCMV
Table 3: Comparison of HCMV DNA and pp65 detection in 55 samples obtained from 5 symptomatic (with HCMV disease) and 119 
samples from 43 asymptomatic (without HCMV disease) patients with active virus replication.
 VIRAL MARKER TOTAL SAMPLES
WITH HCMV DISEASE WITHOUT HCMV DISEASE
HCMV-DNA positive 43 90 133
HCMV-DNA negative 12 29 41
HCMV-pp65 antigen positive 16 14 30
HCMV-pp65 antigen negative 39 105 144BMC Infectious Diseases 2007, 7:138 http://www.biomedcentral.com/1471-2334/7/138
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DNA levels observed, in agreement with previous studies
[13,14,20].
Prospective laboratory monitoring of patients allows for
the timely adoption of therapeutic measures, thus reduc-
ing both the incidence and severity of HCMV disease in
immunocompromised patients. Some studies describe an
earlier rise in HCMV DNA levels, compared to antigene-
mia, in prospectively monitored patients [11,14,17],
while the opposite observation was reported by others
[24,25] In the present study both antigenemia and DNA
were first detected together in 8 out of 11 pp65-positive
cases. Furthermore antigenemia disappered earlier com-
pared to HCMV DNA both in symptomatic and in asymp-
tomatic patients, consistent with other reports [25].
HCMV DNA levels were compared between samples with/
without evidence of pp65-positive cells, considering pp65
antigenemia > 0 as the lowest possible cut-off level for the
prediction of active HCMV infection. Significantly higher
HCMV DNA levels were associated with the presence of
pp65 antigenemia, while the threshold HCMV DNA value
for optimal discrimination of pp65-positive or -negative
samples differed according to the risk group. This observa-
tion suggests that the level of immune suppression can
influence the relationship between HCMV DNA replica-
tion and symptomatic HCMV disease. Accordingly, differ-
ent cut-off HCMV DNA values for risk of disease were
detected in solid organ and stem-cell transplant recipients
[14]. The identification of discrepant threshold levels also
suggests that the optimum cut-off value should be
assessed specifically for each centre and assay [19].
HCMV disease was observed in only 5 transplant recipi-
ents (10.4% of patients showing HCMV reactivation),
who developed symptomatic infection shortly after kid-
ney transplantation (1 patient) or BM/HSC transplanta-
tion (4 pediatric patients). The detection of pp65 was
associated with symptomatic infection, and significantly
higher pp65 levels were observed in symptomatic
patients. A cut-off antigenemia level of 13 positive cells/
200,000 PMNL, comparable to previous results [21],
allowed the best discrimination between symptomatic
and asymptomatic patients. By contrast, both HCMV
DNA detection and the circulating DNA load could not
distinguish between symptomatic and asymptomatic
patients. However, at onset of reactivation, HCMV DNA
load was significantly higher in patients that developed
disease, with best discrimination at about 8,000 copies/
ml, a higher value compared to a previous result (2,000
copies/ml) obtained with a commercial quantitative PCR
[21].
Conclusion
In this study pp65 antigenemia, despite lower sensitivity
for the diagnosis of HCMV active infection compared to
HCMV DNA load, showed better qualitative and quantita-
tive correlation with the presence of symptoms. Only at
onset of active replication was the DNA load able to dis-
criminate patients at risk of developing HCMV disease.
On technical grounds however pp65 antigenemia,
although less expensive, is often difficult to perform in
leukopenic samples and suffers from major pitfalls such
as labor-intensive manual procedure, requirement for
immediate sample processing, subjective interpretation of
results. Thus both tests can be useful for the prospective
monitoring of immunocompromised subjects. Clinically
relevant cut-off levels should be identified for specific
groups of patients and assays, and prospectively validated
for their predictive value over the development of clinical
symptoms of infection.
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